← All trials
NCT06276205
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2024
- Primary completion
- Sep 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Feb 23, 2024
- Last posted
- Feb 23, 2024
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- King Edward Medical UniversityLead sponsor
- King Edward Medical UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.